Recent News

• 08.07.2026 - bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung
• 08.07.2026 - bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung
• 07.27.2026 - bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung
• 07.27.2026 - bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung
• 07.22.2026 - bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD
• 07.22.2026 - bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD
• 07.08.2026 - See what’s happening at bioAffinity Technologies…
• 07.07.2026 - bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues
• 07.02.2026 - See what’s happening at bioAffinity Technologies…
• 06.22.2026 - bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells

Recent Filings

• 08.07.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.07.2026 - 8-K Current report
• 08.07.2026 - EX-99.1 EX-99.1
• 07.31.2026 - 8-K Current report
• 07.27.2026 - 8-K Current report
• 07.27.2026 - EX-99.1 EX-99.1
• 07.22.2026 - 8-K Current report
• 07.22.2026 - EX-99.1 EX-99.1
• 07.07.2026 - 8-K Current report
• 07.07.2026 - EX-99.1 EX-99.1